Clinical Trials Logo

Classic Hodgkin Lymphoma clinical trials

View clinical trials related to Classic Hodgkin Lymphoma.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06164275 Recruiting - Clinical trials for Classic Hodgkin Lymphoma

Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin Lymphoma

Start date: February 6, 2024
Phase: Phase 2
Study type: Interventional

This phase II trial tests how well giving pembrolizumab followed by chemotherapy with doxorubicin, vinblastine and dacarbazine works to treat patients with classical Hodgkin lymphoma. Pembrolizumab is a type of drug called a "monoclonal antibody (mAb)" that uses the body's immune system to help fight and kill cancer cells. Chemotherapy drugs, such as doxorubicin, vinblastine and dacarbazine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing or by stopping them from spreading. Giving pembrolizumab followed by chemotherapy may work to treat patients with classical Hodgkin lymphoma.

NCT ID: NCT05955105 Recruiting - Ovarian Cancer Clinical Trials

A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies

Start date: July 25, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a multicenter, open-label, phase Ib/IIa study. The first part of the study will evaluate the safety, tolerability and preliminary efficacy of ILB2109 and Toripalimab in patients with locally advanced or metastatic solid malignancies. The second part of the study will evaluate the efficacy of ILB2109 and Toripalimab in patients with selected advanced solid malignancies.

NCT ID: NCT05833984 Recruiting - Solid Tumor Clinical Trials

Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas

Start date: May 17, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open-label, multicenter, phase 1b/2 trial of IMM01 (SIRPĪ± Fc) plus tislelizumab in patients with advanced solid tumors and lymphomas.